Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

crine.niddk.nih.gov/pubs/cushings/Cushings_Syndrome_FS.pdf">http://endocrine.niddk.nih.gov/pubs/cushings/Cushings_Syndrome_FS.pdf.  Accessed December 2011.
3.     Boscaro, M. Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial. J Clin Endocrin Metabol. 2009;94(1):115-122.
4.     Newell-Price, J. The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States. Endocrine Reviews. 1998;19(5): 647-672.
5.     Pedroncelli, A. Medical Treatment of Cushing's Disease: Somatostatin Analogues and Pasireotide. Neuroendocrinology. 2010;92(suppl1):120-124.
6.     Lindholm, J. Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study. The Journal of Clinical Endocrinology & Metabolism. 2001; 86(1):117-121.

Novartis Media Relations

Julie Masow

Novartis Corporation

+1 212 830 2465 (direct)

+1 862 579 8456 (mobile)

julie.masow@novartis.com

 

e-mail: us.mediarelations@novartis.com

Nicole Riley

Novartis Oncology

+1 862 778 3110 (direct)

+1 862 926 9040 (mobile)

nicole.riley@novartis.com

 

 

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PARSIPPANY, N.J. , July 30, 2015  Growth ... Rx-to-OTC switches as they bring former prescription users to ... environment, Kline forecasts robust Rx-to-OTC switch activity ... OTC categories emerging along with many new brands entering ... switches occur over the next five years (even those ...
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
(Date:7/30/2015)... , July 30, 2015 ... focused on gynecologic disease, announced today it ... results after the market close on Thursday, ... conference call and webcast at 4:30pm Eastern.Conference ... 2015 at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Sound Surgical Technologies, innovators of ultrasonic body contouring technologies and ...  The original VASER® System was designed to provide patients with smooth, ... a wide array of body contouring applications. , ... Now, the new VASER System has ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to ... the first quarter ended March 31, 2010 as compared ... a 10 percent increase. As of March 31, 2010 , ... posted its financial results for the first quarter ended March ...
Cached Medicine Technology:Body Contouring Taken to the Next Level 2Body Contouring Taken to the Next Level 3Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Between 2012 ... to the Health News Florida on June 17th. Those untreated heroin use ... programs to prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited ... “no recommendations.” No recommendations means CARF found no areas in the OHR program that ... than 3% of all facilities receive. In addition, Ocean Hills was granted the maximum ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. ... 2015 from 10:00 AM to 2:00 PM local time. On the 26th, the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School ... cancer center. TCI joins an elite group of 69 cancer institutions nationwide that ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6
... Chinese researchers, the pumpkin promises more than it shows . ... the scientists from East China Normal University, have revealed that ... the pancreas, as well as increase insulin production. ... report in the journal Chemistry and Industry: "Pumpkin extract is ...
... time Terrence Balcita and Chevela Luong were joined as one at ... not enjoying blackjack or Wayne Newton, but that other Vegas specialty: ... to go with the love." Balcita said. ,Couples tied ... enjoy a 7/7/07 wedding date. ,"This is a historic ...
... earlier Rhode Island Hospital study looking at data from ... per year were seen in emergency departments across the ... which examined emergency department visits from 2000 through 2005, ... the study period, an average of 88,563 each year. ...
... Genzyme Corp. announced top-line data from the first of ... and efficacy of tolevamer liquid, an investigational, non-antibiotic , ... (CDAD). The second Phase 3 study of tolevamer liquid ... year. ,In this first Phase 3 study known ...
... a technique that could be used to confirm whether someone ... which has so far been used mainly in animal models, ... abnormal proteins that progressively kill off brain tissue and are ... as known as Protein Misfolding Cyclic Amplification (PMCA), enables the ...
... disorders in sex cells cause infertility, miscarriage and irregular ... ,A new study from Karolinska Institutet published in ... can arise when sex cells are formed. ... mechanism that ensures that the correct numbers of chromosomes ...
Cached Medicine News:Health News:Vegas Couples Hope Sevens Will Be Lucky Wedding Day 2Health News:Higher Rates of Trampoline Injuries 2Health News:Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients 2Health News:Significant Advances in VCJD Prion Detection 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: